Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy

BACKGROUND: Immunotherapy is an emerging paradigm for the treatment of cancer, but the potential efficacy of many drugs cannot be sufficiently tested in the mouse. We sought to develop a rational combination of motolimod—a novel Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immun...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Monk, Bradley J., Facciabene, Andrea, Brady, William E., Aghajanian, Carol A., Fracasso, Paula M., Walker, Joan L., Lankes, Heather A., Manjarrez, Kristi L., Danet-Desnoyers, Gwenn-äel H., Bell-McGuinn, Katherine M., McCourt, Carolyn K., Malykhin, Alexander, Hershberg, Robert M., Coukos, George
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5437973/
https://ncbi.nlm.nih.gov/pubmed/27702821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1453
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller